Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit.
Local IgA and IgG antibodies against respiratory syncytial virus (RSV) were induced in the respiratory tract of mice following intranasal vaccination with an RSV chimeric FG glycoprotein and cholera toxin B (CTB) as a mucosal adjuvant. Local antibody production was not induced following parenteral immunization with FG administered in alum adjuvant. While both vaccination protocols induced serum antibodies against RSV and protected the lower respiratory tract from RSV infection, only intranasal FG/CTB afforded protection of the upper respiratory tract. These data suggest that vaccination via the mucosal route may be superior to vaccination by a parental route in providing complete protection against RSV.
Oien
N L
NL
Department of Cancer and Infectious Diseases, Upjohn Company, Kalamazoo, MI 49001.
Brideau
R J
RJ
Walsh
E E
EE
Wathen
M W
MW
D000276:Adjuvants, Immunologic; D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002772:Cholera Toxin / Q000276:immunology*; D005260:Female; D006023:Glycoproteins / Q000276:immunology*; D007132:Immunoglobulin Isotypes / Q000096:biosynthesis; D007273:Injections, Intramuscular; D051379:Mice; D008807:Mice, Inbred BALB C; D009092:Mucous Membrane / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000276:immunology; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D012137:Respiratory System / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology*; D014764:Viral Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D006023:Glycoproteins; D007132:Immunoglobulin Isotypes; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic; D014764:Viral Proteins; D014765:Viral Vaccines; D002772:Cholera Toxin